These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 15504850

  • 1. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N, Müller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S.
    Eur J Med Res; 2006 Jun 30; 11(6):236-44. PubMed ID: 16820336
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD, MaxCmin1 and 2 trial groups.
    Basic Clin Pharmacol Toxicol; 2007 Nov 30; 101(5):339-44. PubMed ID: 17910618
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
    von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A.
    Antivir Ther; 2008 Nov 30; 13(8):1039-46. PubMed ID: 19195329
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M, Verweel G, de Groot R, Burger D.
    Antivir Ther; 2006 Nov 30; 11(4):439-45. PubMed ID: 16856617
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.
    Antivir Ther; 2007 Nov 30; 12(8):1237-46. PubMed ID: 18240863
    [Abstract] [Full Text] [Related]

  • 12. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S, De Luca A, Villani P, Bacarelli A, Ragazzoni E, Regazzi M, Cauda R, Navarra P.
    HIV Med; 2008 Apr 30; 9(4):239-45. PubMed ID: 18366448
    [Abstract] [Full Text] [Related]

  • 13. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P.
    Antivir Ther; 2004 Apr 30; 9(2):247-56. PubMed ID: 15134187
    [Abstract] [Full Text] [Related]

  • 14. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F, Girard PM.
    Clin Pharmacol Ther; 2004 Apr 30; 75(4):310-23. PubMed ID: 15060509
    [Abstract] [Full Text] [Related]

  • 15. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K.
    Antivir Ther; 2009 Apr 30; 14(7):1001-4. PubMed ID: 19918104
    [Abstract] [Full Text] [Related]

  • 16. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J, HIV-NAT 017 Study Team.
    Pediatr Infect Dis J; 2008 Jul 30; 27(7):623-8. PubMed ID: 18520443
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C.
    Antivir Ther; 2009 Jul 30; 14(4):603-6. PubMed ID: 19578247
    [Abstract] [Full Text] [Related]

  • 18. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
    Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E, Hill A, Cooper DA, Phanuphak P, Lange JM, Burger DM, Ruxrungtham K.
    AIDS; 2007 Jul 31; 21(12):1535-9. PubMed ID: 17630547
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
    van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D, HIV-NAT 019 Study Team.
    J Antimicrob Chemother; 2008 May 31; 61(5):1145-53. PubMed ID: 18285316
    [Abstract] [Full Text] [Related]

  • 20. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec 31; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.